For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Tafamidis and the formulated version represents a significant breakthrough . These innovative therapies protect the transthyretin protein, halting its damaging build-up and lessening the impact of the illness. Patients are now report